StockNews.com Begins Coverage on BIOLASE (NASDAQ:BIOL)

StockNews.com assumed coverage on shares of BIOLASE (NASDAQ:BIOL) in a report released on Wednesday. The brokerage set a “sell” rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research note on Wednesday, October 2nd.

BIOLASE Stock Up 5.4 %

NASDAQ BIOL opened at $0.01 on Wednesday. The company has a market capitalization of $314,025.80, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a twelve month low of $0.02 and a twelve month high of $1.94. The stock has a fifty day simple moving average of $0.01 and a 200 day simple moving average of $0.04.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.